Moreover, preclinical data have indicated that thiazolidinediones and gliptins do not have beneficial effects, but gliptins, which increase GLP-1 levels in the brain, improve cognitive decline in individuals with diabetes [142]. The gene discussed is GLP1R; the disease is Mental deterioration.